Solid Biosciences develops gene therapy candidates for rare neuromuscular and cardiac diseases, starting with Duchenne muscular dystrophy. SLDB reports earnings on Mon, Nov 2, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for SLDB are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in SLDB in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLDB is in one of them and how their past SLDB trades turned out.
Solid Biosciences is a life sciences company based in Charlestown, Massachusetts, that develops gene therapy candidates for rare neuromuscular and cardiac diseases. Its lead candidate, SGT-003, is designed to treat Duchenne muscular dystrophy by delivering a gene that produces a smaller version of the dystrophin protein. The company is also developing candidates for Friedreich's ataxia and other genetic heart diseases. Its work is aimed at patients living with these rare conditions, many of whom have few treatment options.
